Bernd Giebel,
Group Leader, Institute for Transfusion Medicine,
University Hospital Duisburg-Essen
Bernd Giebel studied biology at the University zu Köln and received his PhD in 1996 at the Institute for Developmental Biology in Köln. He runs a lab at the Institute for Transfusion Medicine at the University Hospital Essen. Since 1999 he works with human hematopoietic stem cells and started in 2009 to explore the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Together with collaboration partners the group demonstrated the therapeutic potential of prepared MSC-EVs in a human GvHD-patient and in different animal models. It is the current goal to optimize the MSC-EV production and characterization process to efficiently translate MSC-EVs into the clinics.
B Giebel is the president of the German Society of Extracellular Vesicles (GSEV) and a co-chair of the exosome working group of the International Society of Gene and Cell Therapy (ISCT) and an active member of the International Society of Extracellular Vesicles (ISEV). Furthermore, he is part of the scientific advisory board of two SME companies, Innovex Therapeutics and Mursla LTD. In 2021 he became a founding director of Exosla LTD.
Therapeutic Potentials of Mesenchymal Stem Cell-derived Extracellular Vesicles
Tuesday, 12 July 2016 at 11:45
Add to Calendar ▼2016-07-12 11:45:002016-07-12 12:45:00Europe/LondonTherapeutic Potentials of Mesenchymal Stem Cell-derived Extracellular VesiclesExtracellular Vesicles 2016 in Cambridge. UKCambridge. UKSELECTBIOenquiries@selectbiosciences.com
MSCs have been used to treat a variety of different diseases such as myocardial infarction, stroke and graft-versus-host disease (GvHD). Initially, MSCs were thought to replace lost cells in damaged tissues. Despite contrary reports regarding the outcome of MSC treatments, MSCs seem to exert their beneficial effects by the secretion of immunosuppressive factors and/or small extracellular vesicles (EVs, 70-150 nm), such as exosomes and microvesicles, rather than by interacting into affected tissues. After setting up techniques for the characterization and large scale preparation of EVs, we have treated a steroid-refractory GvHD patient with EVs/exosomes enriched from MSC supernatants (MSC-EVs). In addition we investigate the MSC-EVs’ therapeutic potential to exert neuroprotective functions in animal models for ischemic stroke and preterm brain injury. So far, we observed beneficial effects in all settings. In the murine stroke model we performed a side by side comparison of the therapeutic effect of MSCs and their EVs and did not recognize any differences, both improved the symptoms significantly. At the functional level MSC-EVs were shown to exert immunosuppressive functions in vivo and in vitro.
Add to Calendar ▼2016-07-12 00:00:002016-07-13 00:00:00Europe/LondonExtracellular Vesicles 2016Extracellular Vesicles 2016 in Cambridge. UKCambridge. UKSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-07-12 11:45:002016-07-12 12:45:00Europe/LondonTherapeutic Potentials of Mesenchymal Stem Cell-derived Extracellular VesiclesExtracellular Vesicles 2016 in Cambridge. UKCambridge. UKSELECTBIOenquiries@selectbiosciences.com
